From: Postoperative intubation time is associated with acute kidney injury in cardiac surgical patients
Time to first extubation | (1) ≤4 h n =94 | (2)>4 h to ≤8 h n =287 | (3) >8 h to ≤12 h n =105 | (4) >12 h to ≤16 h n =45 | (5) n >16 n =53 | Significance (within group differences) | Significance (between different times to extubation) |
---|---|---|---|---|---|---|---|
Age (years) | 63 (58 to 68) | 68 (66 to 70) | 71 (68 to 73) | 68 (65 to 73) | 71 (67 to 74) | P <0.001 | (1) vs. (2) (3) (4) (5) |
(2) vs. (1) (3) | |||||||
(3) vs. (1) (2) | |||||||
(4) vs. (1) | |||||||
(5) vs. (1) | |||||||
Additive Euroscore | 4 (3 to 5) | 5 (4 to 5) | 6 (5 to 6) | 5 (4 to 6) | 7 (6 to 9) | P <0.001 | (1) vs. (2) (3) (4) (5) |
(2) vs. (1) (3) (5) | |||||||
(3) vs. (1) (2) | |||||||
(4) vs. (1) (5) | |||||||
(5) vs. (1) (2) (4) | |||||||
eGFR (ml/min/1.73 m2) | 86.2 (81.5 to 90.4) | 80.4 (78.0 to 85.2) | 74.6 (71.4 to 81.2) | 84.1 (76.9 to 89.1) | 67.6 (57.3 to 90.3) | P =0.02 | (1) vs. (2) (3) (5) |
(2) vs.(1) | |||||||
(3) vs. (1) | |||||||
(5) vs. (1) | |||||||
Duration of surgery (min) | 222 (205 to 240) | 252 (244 to 260) | 260 (246 to 276) | 263 (248 to 280) | 291 (270 to 385) | P <0.001 | (1) vs. (2) (3) (4) (5) |
(2) vs. (1) (5) | |||||||
(3) vs. (1) (5) | |||||||
(4) vs. (1) (5) | |||||||
(5) vs. (1) (2) (3) (4) | |||||||
Drainage loss (ml) | 800 (700 to 900) | 800 (800 to 900) | 900 (850 to 1000) | 900 (745 to 941) | 1000 (773 to 1205) | P =0.02 | (1) vs. (3) (5) |
(2) vs. (3) (5) | |||||||
(3) vs. (1) (2) | |||||||
(5) vs. (1) (2) | |||||||
Blood products (unit) | 1 (0 to 2) | 2 (1 to 2) | 2 (2 to 3) | 2 (2 to 4) | 7 (6 to 9) | P <0.001 | (1) vs. (2) (3) (4) (5) |
(2) vs. (1) (3) (5) | |||||||
(3) vs. (1) (2) (5) | |||||||
(4) vs. (1) (5) | |||||||
(5) vs. (1) (2) (3) (4) | |||||||
MAP POP (mmHg) | 76.5 (73.8 to 77.7) | 74.4 (73.7 to 75.1) | 73.6 (72.4 to 75.1) | 76.4 (75.3 to 78.3) | 74.0 (71.4 to 75.9) | P =0.02 | (1) vs. (2) (3) (5) |
(2) vs. (1) | |||||||
(3) vs. (1) (4) | |||||||
(4) vs. (3) | |||||||
(5) vs. (1) | |||||||
CVP POP (mmHg) | 13.9 (13.2 to 14.7) | 14.4 (14.0 to 14.8) | 15.2 (14.9 to 15.9) | 15.6 (14.6 to 16.1) | 16.9 (15.6 to 18.0) | P <0.001 | (1) vs. (3) (4) (5) |
(2) vs. (3) (4) (5) | |||||||
(3) vs. (1) (2) (5) | |||||||
(4) vs. (1) (2) | |||||||
(5) vs. (1) (2) (3) | |||||||
RPP POP (mmHg) | 62.4 (60.0 to 65.1) | 60.1 (59.5 to 61.3) | 57.9 (56.8 to 59.6) | 60.6 (58.3 to 63.4) | 57.8 (53.6 to 59.5) | P <0.001 | (1) vs. (3) (5) |
(2) vs. (3) (5) | |||||||
(3) vs. (1) (2) | |||||||
(4) vs. (5) | |||||||
(5) vs. (1) (2) (4) | |||||||
Dobutamine - POP | Â | Â | Â | Â | Â | P <0.001 | Â |
0 | 39 (41.5%) | 108 (37.6%) | 26 (13.3%) | 12 (26.7%) | 14 (26.4%) | ||
<15 mg/h | 28 (29.8%) | 94 (32.8%) | 32 (16.4%) | 14 (31.1%) | 16 (30.2%) | ||
15 - 30 mg/h | 23 (24.5%) | 72 (25.1%) | 41 (21%) | 17 (37.8%) | 12 (22.6%) | ||
>30 mg/h | 4 (4.2%) | 14 (4.9%) | 6 (3.1%) | 2 (4.4%) | 11 (20.8%) | ||
Noradrenaline - POP | Â | Â | Â | Â | Â | P <0.001 | Â |
0 | 18 (19.1%) | 57 (19.9%) | 9 (4.6%) | 3 (6.7%) | 3 (5.7%) | ||
<0.3 mg/h | 50 (53.2%) | 136 (47.4%) | 44 (22.6%) | 23 (51.1%) | 9 (17%) | ||
0.3 - 0.6 mg/h | 18 (19.1%) | 68 (23.7%) | 33 (16.9%) | 13 (28.9%) | 9 (17%) | ||
>0.6 mg/h | 8 (8.5%) | 26 (9.1%) | 19 (9.7%) | 6 (13.3%) | 32 (60.4%) | ||
AKI stage | Â | Â | Â | Â | Â | P <0.001 | Â |
0 | 78 (83%) | 212 (73.9%) | 75 (71.5%) | 34 (75.5%) | 20 (37.7%) | Â | |
1 | 8 (8.5%) | 45 (15.7%) | 18 (17,1%) | 8 (17.8%) | 6 (11.3%) | ||
2 | 1 (1.1%) | 5 (1.7%) | 0 (0%) | 0 (0%) | 1 (1.9%) | ||
3 | 7 (7.4%) | 25 (8.7%) | 12 (11.4%) | 3 (6.7%) | 26 (49.1%) |